ISSN: 2332-0877

Journal des maladies infectieuses et de la thérapie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Can Energetic Vaccines, Based on Physics, be the Sound Options for COVID-19 and Other Pandemics, in the Absence of Pharmaceutical Vaccines?

Savely Yurkovsky

The aim of the study is to rapidly produce an energetic SARS-CoV-2 vaccine for an urgent clinical trial.

The methods used to conduct the study: (1) a process of serial dilutions in water media and mechanical impacts, as used in homeopathic preparation from viral culture; (2) imprint of electromagnetic field of the virus through a therapeutic frequency imprinting device into water media, without physical exposure of the virus (US patent, August 2020, number pending).

Results of the study: This method presents substantial scientific and clinical support for the efficacy of an energetic vaccine. Among this, laboratory evidence for specific immune response induced by analogous energetic vaccines prepared from influenza viruses and other microorganisms. Both basic research and clinical evidence is presented on behalf of therapeutic frequency imprinting technology in its ability to induce positive biological effects through microbial energetic vaccines.

Other relevant considerations: Besides the fact that energetic vaccines can literally be produced within minutes, they have a very low safety risk and a virtually non-existent cost factor. Note the fact that a few pharmaceutical vaccine trials were halted due to volunteer illness. Also, the novel vaccines can be readily mass distributed and administered. Furthermore, in the event of continued mutation of the virus that may present a considerable challenge to sustaining the effect of pharmaceutical vaccines, the energetic vaccines can be rapidly remade.

Conclusion: A positive clinical trial would set a precedent in the prevention and resolution of future pandemics or occurrences of infections carrying high morbidity or mortality such as Ebola, Zika and other viruses in the absence of effective vaccines. Likewise, the method can be extended to increasing incidences of antibiotic and antifungal resistant infections as well as vector-borne endemics such as Lyme disease and others.

The method, due to its ontological synergism between molecular and electromagnetic biology is fully in line with physicians’ training in infectious diseases that would render its introduction in their medical practice intuitive.